Dana Rizk, MD, professor of medicine at the University of Alabama at Birmingham, discusses the approval of Fabhalta (iptacopan) for adults with IgA nephropathy. Iptacopan, a Factor B inhibitor of the alternative complement pathway, received initial FDA approval in 2023 for paroxysmal nocturnal hemoglobinuria. The accelerated approval of iptacopan is based on results from the interim analysis of the Phase 3 APPLAUSE-IgAN clinical trial.